Chaft JE, et al. - Researchers analyzed the medical records of patients with resected non-small cell lung cancer (NSCLC) harboring an ALK rearrangement or a driver mutation in EGFR or KRAS, to compare the prognosis of early-stage ALK-positive lung cancers vs KRAS- and EGFR-mutant lung cancers. For each genotype, recurrence-free survival (RFS) was estimated. Relapse within 5 years was reported in one-third of resected ALK-, KRAS- or EGFR-positive lung cancer patients. They also found that relative to other clinically relevant genomic subsets in a large series of resected NSCLC, ALK rearrangements were associated with a trend toward inferior disease outcomes ie, a numerically shorter relapse-free survival was observed among ALK-positive patients vs other groups. No statistical difference was found in overall survival across molecular groups.